Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-40253
Key Product Details
Sample Type & Volume Required Per Well
Serum, plasma, tissue homogenates and other biological fluids (100 uL)
Sensitivity
0.108 ng/mL (example only; lot dependent)
Assay Range
0.312 - 20 ng/mL (example only; lot dependent)
Product Specifications
Assay Type
Sandwich ELISA
Kit Type
ELISA Kit (Colorimetric)
Reactivity
Human
Description
The Ready-To-Use ELISA kit offers pre-diluted detection reagents and a shorter experimental time.
Assay Length: 3 hours
Assay Length: 3 hours
Precision
Intra-Assay Precision (Precision within an assay) %CV < 10 (example only; lot dependent)
Inter-Assay Precision (Precision between assays) %CV < 12 (example only; lot dependent)
Scientific Data Images for Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric)
ELISA: Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric) [NBP3-40253]
ELISA: Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric) [NBP3-40253] - Standard Curve ReferenceKit Contents for Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric)
- Detection Solution A
- Detection Solution B
- Instruction manual
- Plate sealer for 96 wells
- Pre-coated 96T strip plate
- Standard
- Standard Diluent
- Stop Solution
- TMB Substrate
- Wash Buffer (30 x concentrate)
Preparation and Storage
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Storage of components varies. See protocol for specific instructions.
Background: TLR8
TLR8 is highly similar to TLR7 and both pathways are mediated by the adapter protein MyD88 to signal through IFN regulatory factor 7 (IRF7) and nuclear factor (NF)-kappaB (1-3,5). However, TLR7 recognizes guanosine and GU-rich ssRNA, while TLR8 recognizes uridine and AU-rich sequences (2,5). TLR7/TLR8 agonists, including derivatives of the immunostimulatory imiquimod, have been shown to be a promising cancer therapy capable of providing anticancer signals to antigen presenting cells (APCs), with many agonists being tested in both pre-clinical and clinical trials (6). Similarly, studies suggest that agonists for TLR8, in combination with other individual TLR agonists and antagonists, may also be useful for treating inflammatory allergic diseases, such as allergic rhinitis (7).
References
1. Sakaniwa, K., & Shimizu, T. (2020). Targeting the innate immune receptor TLR8 using small-molecule agents. Acta crystallographica. Section D, Structural biology, 76(Pt 7). https://doi.org/10.1107/S2059798320006518
2. Cervantes, J. L., Weinerman, B., Basole, C., & Salazar, J. C. (2012). TLR8: the forgotten relative revindicated. Cellular & molecular immunology. https://doi.org/10.1038/cmi.2012.38
3. Ohto, U., Tanji, H., & Shimizu, T. (2014). Structure and function of toll-like receptor 8. Microbes and infection. https://doi.org/10.1016/j.micinf.2014.01.007
4. Uniprot (Q9NR97)
5. Jannuzzi, G. P., de Almeida, J., Paulo, L., de Almeida, S. R., & Ferreira, K. S. (2020). Intracellular PRRs Activation in Targeting the Immune Response Against Fungal Infections. Frontiers in cellular and infection microbiology. https://doi.org/10.3389/fcimb.2020.591970
6. Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020). Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology. https://doi.org/10.1080/2162402X.2020.1796002
7. Golshiri-Isfahani, A., Amizadeh, M., & Arababadi, M. K. (2018). The roles of toll like receptor 3, 7 and 8 in allergic rhinitis pathogenesis. Allergologia et immunopathologia. https://doi.org/10.1016/j.aller.2017.09.026
Long Name
Toll-like Receptor 8
Alternate Names
CD288
Gene Symbol
TLR8
Additional TLR8 Products
Product Documents for Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric)
Product Specific Notices for Human TLR8 - Ready-To-Use ELISA Kit (Colorimetric)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.
Loading...
Loading...
Loading...
Loading...